Company
Akiram Therapeutics
Claim, correct or request removal
Record updated 19 September 2026
About
Akiram has developed a new type of targeted radioimmunotherapy with the potential to become first-in-class. In animal studies, the survival rate has been 100%, and the tumours have been eradicated with just one treatment.
Loading relationship preview